Landmark study links DAAs to better survival in hep C patients

The results counter an inflammatory Cochrane review that questioned the drugs, say gastroenterologists

The first prospective longitudinal study of outcomes from treatment with direct-acting antivirals (DAAs) suggests the drugs could halve mortality rates among patients with hepatitis C.